Saniona
BioStock: Saniona has started dosing in the SAN711 trial (Cision)

2024-10-08 08:31

BioStock: Saniona has started dosing in the SAN711 trial


Saniona has initiated dosing of the first subjects with SAN711 in a phase I multiple ascending dose biomarker study, aiming to release topline data by the end of the year. The CEO, Thomas Feldthus, see this as a milestone and a crucial step towards the goal of starting a clinical proof-of-concept study in children with absence seizures next year. – This study with SAN711 in healthy volunteers offers valuable insights into the appropriate dosing for our phase II trial, helping to ensure positive outcomes.


Read the full article at biostock.se: https://www.biostock.se/en/2024/10/saniona-has-started-dosing-in-the-san711-trial/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/


support.se@cision.com
© Copyright

Saniona - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -